HRP20220463T1 - Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa - Google Patents

Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa Download PDF

Info

Publication number
HRP20220463T1
HRP20220463T1 HRP20220463TT HRP20220463T HRP20220463T1 HR P20220463 T1 HRP20220463 T1 HR P20220463T1 HR P20220463T T HRP20220463T T HR P20220463TT HR P20220463 T HRP20220463 T HR P20220463T HR P20220463 T1 HRP20220463 T1 HR P20220463T1
Authority
HR
Croatia
Prior art keywords
phenyl
dione
carboxamide
ethyl
acid
Prior art date
Application number
HRP20220463TT
Other languages
English (en)
Inventor
Melanie KESSLER
Catherine Roch
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of HRP20220463T1 publication Critical patent/HRP20220463T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Claims (18)

1. Farmaceutska kombinacija, naznačena time, da sadrži prvi aktivni sastojak koji je N-[1-(5-cijano-piridin-2ilmetil)-1H-pirazol-3-il]-2-[4-(1-trifluorometil-ciklopropil)-fenil]-acetamid ili njegova farmaceutski prihvatljiva sol i drugi aktivni sastojak koji ima antiepileptički učinak, ili njegovu farmaceutski prihvatljivu sol.
2. Farmaceutska kombinacija prema patentnom zahtjevu 1, naznačena time, da se drugi aktivni sastojak bira iz skupine koju čine 5H-dibenzo[b,f]azepin-5-karboksamid, (RS)-3-etil-3-metil-pirolidin-2,5-dion, 6-(2,3-diklorofenil)-1,2,4-triazin-3,5-diamin, (S)-2-(2-oksopirolidin-1-il)butanamid, 10,11-dihidro-10-okso-5H-dibenz[b,f]azepin-5-karboksamid, 2-propilpentanska kiselina, N-(5-sulfamoil-1,3,4-tiadiazol-2-il)acetamid, (2S)-2-[(4R)-2-okso-4-propilpirolidin-1-il]butanamid, 7-kloro-1-metil-5-fenil-1,5-benzodiazepin-2,4-dion, 5-(2-klorofenil)-7-nitro-1,3-dihidro-1,4-benzodiazepin-2-on, (S)-10-acetoksi-10,11-dihidro-5H-dibenz[b,f]azepin-5-karboksamid, (3-karbamoiloksi-2-fenilpropil)karbamat, 1-(aminometil)cikloheksanoctena kiselina, (R)-2-acetamido-N-benzil-3-metoksipropanamid, 5’-(2-cijanofenil)-1’-fenil-2,3’-bipiridinil-6’(1’H)-on, 5-etil-5-fenil-1,3-diazinan-2,4,6-trion, 5,5-difenilimidazolidin-2,4-dion, 2-(2-oksopirolidin-1-il)acetamid, (3S)-3-(aminometil)-5-metilheksanska kiselina, 5-etil-5-fenil-1,3-diazinan-4,6-dion, etil (2-amino-4-((4-fluorobenzil)amino)fenil)karbamat, 1-(2,6-difluorobenzil)-1H-1,2,3-triazol-4-karboksamid, (RS)-(E)-4,4-dimetil-1-[3,4(metilendioksi)-fenil]-1-penten-3-ol, (3R)-1-[4,4-bis(3-metil-2-tienil)-3-buten-1-il]-3-piperidinkarboksilna kiselina, 2,3:4,5-bis-O-(1-metiletiliden)-β-D-fruktopiranoza sulfamat, (RS)-4-aminoheks-5-enska kiselina, i benzo[d]izoksazol-3-ilmetansulfonamid; ili farmaceutski prihvatljiva sol od bilo kojega od prethodno navedenih.
3. Farmaceutska kombinacija prema patentnom zahtjevu 1, naznačena time, da se drugi aktivni sastojak bira iz skupine koju čine 5H-dibenzo[b,f]azepin-5-karboksamid, (RS)-3-etil-3-metil-pirolidin-2,5-dion, 6-(2,3-diklorofenil)-1,2,4-triazin-3,5-diamin, (S)-2-(2-oksopirolidin-1-il)butanamid, 10,11-dihidro-10-okso-5H-dibenz[b,f]azepin-5-karboksamid, i 2-propilpentanska kiselina; ili farmaceutski prihvatljiva sol od bilo kojega od prethodno navedenih.
4. Farmaceutska kombinacija prema patentnom zahtjevu 1, naznačena time, da se drugi aktivni sastojak bira iz skupine koju čine (RS)-3-etil-3-metil-pirolidin-2,5-dion, 6-(2,3-diklorofenil)-1,2,4-triazin-3,5-diamin, (S)-2-(2-oksopirolidin-1-il)butanamid, 2-propilpentanska kiselina, i 5-(2-klorofenil)-7-nitro-1,3-dihidro-1,4-benzodiazepin-2-on; ili farmaceutski prihvatljiva sol od bilo kojega od prethodno navedenih.
5. Farmaceutska kombinacija prema patentnom zahtjevu 1, naznačena time, da se drugi aktivni sastojak bira iz skupine koju čine (S)-2-(2-oksopirolidin-1-il)butanamid, i 2-propilpentanska kiselina; ili farmaceutski prihvatljiva sol od bilo kojega od prethodno navedenih.
6. Farmaceutska kombinacija prema patentnom zahtjevu 1, naznačena time, da drugi aktivni sastojak je (S)-2-(2-oksopirolidin-1-il)butanamid ili njegova farmaceutski prihvatljiva sol.
7. Farmaceutska kombinacija prema patentnom zahtjevu 1, naznačena time, da drugi aktivni sastojak je 2-propilpentanska kiselina ili njezina farmaceutski prihvatljiva sol.
8. Farmaceutska kombinacija prema patentnom zahtjevu 1, naznačena time, da drugi aktivni sastojak je (2S)-2-[(4R)-2-okso-4-propilpirolidin-1-il]butanamid ili njegova farmaceutski prihvatljiva sol.
9. Farmaceutska kombinacija prema bilo kojem od patentnih zahtjeva 1 do 8, naznačena time, da su prvi i drugi aktivni sastojak sadržani u jedinstvenom farmaceutskom pripravku.
10. Farmaceutska kombinacija prema bilo kojem od patentnih zahtjeva 1 do 8, naznačena time, da su prvi i drugi aktivni sastojak sadržani u odvojenim farmaceutskim pripravcima.
11. Farmaceutska kombinacija prema bilo kojem od patentnih zahtjeva 1 do 10, naznačena time, da je za uporabu kao lijek.
12. Farmaceutska kombinacija prema bilo kojem od patentnih zahtjeva 1 do 10, naznačena time, da je za uporabu u prevenciji i/ili liječenju epilepsije.
13. Farmaceutska kombinacija prema bilo kojem od patentnih zahtjeva 1 do 10, naznačena time, da je za uporabu u prevenciji i/ili liječenju toničko-kloničkih konvulzija i/ili malih napadaja konvulzija (apsensa).
14. Farmaceutski pripravak, naznačen time, da kao aktivni sastojak, sadrži N-[1-(5-cijano-piridin-2ilmetil)-1H-pirazol-3-il]-2-[4-(1-trifluorometil-ciklopropil)-fenil]-acetamid, ili njegovu farmaceutski prihvatljivu sol, i najmanje jedno terapijski inertno pomoćno sredstvo, za uporabu kao lijek, pri čemu se farmaceutski pripravak treba davati u kombinaciji s drugim farmaceutskim pripravkom koji kao aktivni sastojak, sadrži 5H-dibenzo[b,f]azepin-5-karboksamid, (RS)-3-etil-3-metil-pirolidin-2,5-dion, 6-(2,3-diklorofenil)-1,2,4-triazin-3,5-diamin, (S)-2-(2-oksopirolidin-1-il)butanamid, 10,11-dihidro-10-okso-5H-dibenz[b,f]azepin-5-karboksamid, 2-propilpentanska kiselina, N-(5-sulfamoil-1,3,4-tiadiazol-2-il)acetamid, (2S)-2-[(4R)-2-okso-4-propilpirolidin-1-il]butanamid, 7-kloro-1-metil-5-fenil-1,5-benzodiazepin-2,4-dion, 5-(2-klorofenil)-7-nitro-1,3-dihidro-1,4-benzodiazepin-2-on, (S)-10-acetoksi-10,11-dihidro-5H-dibenz[b,f]azepin-5-karboksamid, (3-karbamoiloksi-2-fenilpropil)karbamat, 1-(aminometil)cikloheksanoctena kiselina, (R)-2-acetamido-N-benzil-3-metoksipropanamid, 5’-(2-cijanofenil)-1’-fenil-2,3’-bipiridinil-6’(1’H)-on, 5-etil-5-fenil-1,3-diazinan-2,4,6-trion, 5,5-difenilimidazolidin-2,4-dion, 2-(2-oksopirolidin-1-il)acetamid, (3S)-3-(aminometil)-5-metilheksanska kiselina, 5-etil-5-fenil-1,3-diazinan-4,6-dion, etil (2-amino-4-((4-fluorobenzil)amino)fenil)karbamat, 1-(2,6-difluorobenzil)-1H-1,2,3-triazol-4-karboksamid, (RS)-(E)-4,4-dimetil-1-[3,4(metilendioksi)-fenil]-1-penten-3-ol, (3R)-1-[4,4-bis(3-metil-2-tienil)-3-buten-1-il]-3-piperidinkarboksilna kiselina, 2,3:4,5-bis-O-(1-metiletiliden)-β-D-fruktopiranoza sulfamat, (RS)-4-aminoheks-5-enska kiselina, ili benzo[d]izoksazol-3-ilmetansulfonamid; ili njihovu farmaceutski prihvatljivu sol, i najmanje jedno terapijski inertno pomoćno sredstvo.
15. Farmaceutski pripravak, naznačen time, da kao aktivni sastojak, sadrži 5H-dibenzo[b,f]azepin-5-karboksamid, (RS)-3-etil-3-metil-pirolidin-2,5-dion, 6-(2,3-diklorofenil)-1,2,4-triazin-3,5-diamin, (S)-2-(2-oksopirolidin-1-il)butanamid, 10,11-dihidro-10-okso-5H-dibenz[b,f]azepin-5-karboksamid, 2-propilpentanska kiselina, N-(5-sulfamoil-1,3,4-tiadiazol-2-il)acetamid, (2S)-2-[(4R)-2-okso-4-propilpirolidin-1-il]butanamid, 7-kloro-1-metil-5-fenil-1,5-benzodiazepin-2,4-dion, 5-(2-klorofenil)-7-nitro-1,3-dihidro-1,4-benzodiazepin-2-on, (S)-10-acetoksi-10,11-dihidro-5H-dibenz[b,f]azepin-5-karboksamid, (3-karbamoiloksi-2-fenilpropil)karbamat, 1-(aminometil)cikloheksanoctena kiselina, (R)-2-acetamido-N-benzil-3-metoksipropanamid, 5’-(2-cijanofenil)-1’-fenil-2,3’-bipiridinil-6’(1’H)-on, 5-etil-5-fenil-1,3-diazinan-2,4,6-trion, 5,5-difenilimidazolidin-2,4-dion, 2-(2-oksopirolidin-1-il)acetamid, (3S)-3-(aminometil)-5-metilheksanska kiselina, 5-etil-5-fenil-1,3-diazinan-4,6-dion, etil (2-amino-4-((4-fluorobenzil)amino)fenil)karbamat, 1-(2,6-difluorobenzil)-1H-1,2,3-triazol-4-karboksamid, (RS)-(E)-4,4-dimetil-1-[3,4(metilendioksi)-fenil]-1-penten-3-ol, (3R)-1-[4,4-bis(3-metil-2-tienil)-3-buten-1-il]-3-piperidinkarboksilna kiselina, 2,3:4,5bis-O-(1-metiletiliden)-β-D-fruktopiranoza sulfamat, (RS)-4-aminoheks-5-enska kiselina, ili benzo[d]izoksazol-3-ilmetansulfonamid; ili njihovu farmaceutski prihvatljivu sol, i najmanje jedno terapijski inertno pomoćno sredstvo, za uporabu kao lijek, pri čemu se farmaceutski pripravak treba davati u kombinaciji s drugim farmaceutskim pripravkom koji kao aktivni sastojak, sadrži N-[1-(5-cijano-piridin-2ilmetil)-1H-pirazol-3-il]-2-[4-(1-trifluorometil-ciklopropil)-fenil]-acetamid, ili njegovu farmaceutski prihvatljivu sol, i najmanje jedno terapijski inertno pomoćno sredstvo.
16. Komplet od dijelova, naznačen time, da sadrži prvi farmaceutski pripravak koji kao aktivni sastojak, sadrži N-[1-(5-cijano-piridin-2ilmetil)-1H-pirazol-3-il]-2-[4-(1-trifluorometil-ciklopropil)-fenil]-acetamid, ili njegovu farmaceutski prihvatljivu sol, i najmanje jedno terapijski inertno pomoćno sredstvo; i drugi farmaceutski pripravak koji kao aktivni sastojak, sadrži 5H-dibenzo[b,f]azepin-5-karboksamid, (RS)-3-etil-3-metil-pirolidin-2,5-dion, 6-(2,3-diklorofenil)-1,2,4-triazin-3,5-diamin, (S)-2-(2-oksopirolidin-1-il)butanamid, 10,11-dihidro-10-okso-5H-dibenz[b,f]azepin-5-karboksamid, 2-propilpentanska kiselina, N-(5-sulfamoil-1,3,4-tiadiazol-2-il)acetamid, (2S)-2-[(4R)-2-okso-4-propilpirolidin-1-il]butanamid, 7-kloro-1-metil-5-fenil-1,5-benzodiazepin-2,4-dion, 5-(2-klorofenil)-7-nitro-1,3-dihidro-1,4-benzodiazepin-2-on, (S)-10-acetoksi-10,11-dihidro-5H-dibenz[b,f]azepin-5-karboksamid, (3-karbamoiloksi-2-fenilpropil)karbamat, 1-(aminometil)cikloheksanoctena kiselina, (R)-2-acetamido-N-benzil-3-metoksipropanamid, 5’-(2-cijanofenil)-1’-fenil-2,3’-bipiridinil-6’(1’H)-on, 5-etil-5-fenil-1,3-diazinan-2,4,6-trion, 5,5-difenilimidazolidin-2,4-dion, 2-(2-oksopirolidin-1-il)acetamid, (3S)-3-(aminometil)-5-metilheksanska kiselina, 5-etil-5-fenil-1,3-diazinan-4,6-dion, etil (2-amino-4-((4-fluorobenzil)amino)fenil)karbamat, 1-(2,6-difluorobenzil)-1H-1,2,3-triazol-4-karboksamid, (RS)-(E)-4,4-dimetil-1-[3,4(metilendioksi)-fenil]-1-penten-3-ol, (3R)-1-[4,4-bis(3-metil-2-tienil)-3-buten-1-il]-3-piperidinkarboksilna kiselina, 2,3:4,5-bis-O-(1-metiletiliden)-β-D-fruktopiranoza sulfamat, (RS)-4-aminoheks-5-enska kiselina, ili benzo[d]izoksazol-3-ilmetansulfonamid; ili njihovu farmaceutski prihvatljivu sol, i najmanje jedno terapijski inertno pomoćno sredstvo.
17. Farmaceutski pripravak koji kao aktivni sastojak, sadrži N-[1-(5-cijano-piridin-2ilmetil)-1H-pirazol-3-il]-2-[4-(1-trifluorometil-ciklopropil)-fenil]-acetamid, ili njegovu farmaceutski prihvatljivu sol, i najmanje jedno terapijski inertno pomoćno sredstvo, naznačen time, da je za uporabu u prevenciji i/ili liječenju epilepsije, pri čemu se farmaceutski pripravak treba davati u kombinaciji s drugim farmaceutskim pripravkom koji kao aktivni sastojak, sadrži 5H-dibenzo[b,f]azepin-5-karboksamid, (RS)-3-etil-3-metil-pirolidin-2,5-dion, 6-(2,3-diklorofenil)-1,2,4-triazin-3,5-diamin, (S)-2-(2-oksopirolidin-1-il)butanamid, 10,11-dihidro-10-okso-5H-dibenz[b,f]azepin-5-karboksamid, 2-propilpentanska kiselina, N-(5-sulfamoil-1,3,4-tiadiazol-2-il)acetamid, (2S)-2-[(4R)-2-okso-4-propilpirolidin-1-il]butanamid, 7-kloro-1-metil-5-fenil-1,5-benzodiazepin-2,4-dion, 5-(2-klorofenil)-7-nitro-1,3-dihidro-1,4-benzodiazepin-2-on, (S)-10-acetoksi-10,11-dihidro-5H-dibenz[b,f]azepin-5-karboksamid, (3-karbamoiloksi-2-fenilpropil)karbamat, 1-(aminometil)cikloheksanoctena kiselina, (R)-2-acetamido-N-benzil-3-metoksipropanamid, 5’-(2-cijanofenil)-1’-fenil-2,3’-bipiridinil-6’(1’H)-on, 5-etil-5-fenil-1,3-diazinan-2,4,6-trion, 5,5-difenilimidazolidin-2,4-dion, 2-(2-oksopirolidin-1-il)acetamid, (3S)-3-(aminometil)-5-metilheksanska kiselina, 5-etil-5-fenil-1,3-diazinan-4,6-dion, etil (2-amino-4-((4-fluorobenzil)amino)fenil)karbamat, 1-(2,6-difluorobenzil)-1H-1,2,3-triazol-4-karboksamid, (RS)-(E)-4,4-dimetil-1-[3,4(metilendioksi)-fenil]-1-penten-3-ol, (3R)-1-[4,4-bis(3-metil-2-tienil)-3-buten-1-il]-3-piperidinkarboksilna kiselina, 2,3:4,5-bis-O-(1-metiletiliden)-β-D-fruktopiranoza sulfamat, (RS)-4-aminoheks-5-enska kiselina, ili benzo[d]izoksazol-3-ilmetansulfonamid; ili njihovu farmaceutski prihvatljivu sol, i najmanje jedno terapijski inertno pomoćno sredstvo.
18. Farmaceutski pripravak koji kao aktivni sastojak, sadrži 5H-dibenzo[b,f]azepin-5-karboksamid, (RS)-3-etil-3-metil-pirolidin-2,5-dion, 6-(2,3-diklorofenil)-1,2,4-triazin-3,5-diamin, (S)-2-(2-oksopirolidin-1-il)butanamid, 10,11-dihidro-10-okso-5H-dibenz[b,f]azepin-5-karboksamid, 2-propilpentanska kiselina, N-(5-sulfamoil-1,3,4-tiadiazol-2-il)acetamid, (2S)-2-[(4R)-2-okso-4-propilpirolidin-1-il]butanamid, 7-kloro-1-metil-5-fenil-1,5-benzodiazepin-2,4-dion, 5-(2-klorofenil)-7-nitro-1,3-dihidro-1,4-benzodiazepin-2-on, (S)-10-acetoksi-10,11-dihidro-5H-dibenz[b,f]azepin-5-karboksamid, (3-karbamoiloksi-2-fenilpropil)karbamat, 1-(aminometil) cikloheksanoctena kiselina, (R)-2-acetamido-N-benzil-3-metoksipropanamid, 5’-(2-cijanofenil)-1’-fenil-2,3’-bipiridinil-6’(1’H)-on, 5-etil-5-fenil-1,3-diazinan-2,4,6-trion, 5,5-difenilimidazolidin-2,4-dion, 2-(2-oksopirolidin-1-il)acetamid, (3S)-3-(aminometil)-5-metilheksanska kiselina, 5-etil-5-fenil-1,3-diazinan-4,6-dion, etil (2-amino-4-((4-fluorobenzil)amino)fenil)karbamat, 1-(2,6-difluorobenzil)-1H-1,2,3-triazol-4-karboksamid, (RS)-(E)-4,4-dimetil-1-[3,4(metilendioksi)-fenil]-1-penten-3-ol, (3R)-1-[4,4-bis(3-metil-2-tienil)-3-buten-1-il]-3-piperidinkarboksilna kiselina, 2,3:4,5-bis-O-(1-metiletiliden)-β-D-fruktopiranoza sulfamat, (RS)-4-aminoheks-5-enska kiselina, ili benzo[d]izoksazol-3-ilmetansulfonamid; ili njihovu farmaceutski prihvatljivu sol, i najmanje jedno terapijski inertno pomoćno sredstvo, naznačen time, da je za uporabu u prevenciji i/ili liječenju epilepsije, pri čemu se farmaceutski pripravak treba davati u kombinaciji s drugim farmaceutskim pripravkom koji kao aktivni sastojak, sadrži N-[1-(5-cijano-piridin-2ilmetil)-1H-pirazol-3-il]-2-[4-(1-trifluorometil-ciklopropil)-fenil]-acetamid, ili njegovu farmaceutski prihvatljivu sol, i najmanje jedno terapijski inertno pomoćno sredstvo.
HRP20220463TT 2016-12-16 2017-12-15 Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa HRP20220463T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2016081455 2016-12-16
EP17828874.2A EP3554490B1 (en) 2016-12-16 2017-12-15 Pharmaceutical combination comprising a t-type calcium channel blocker
PCT/EP2017/082981 WO2018109152A1 (en) 2016-12-16 2017-12-15 Pharmaceutical combination comprising a t-type calcium channel blocker

Publications (1)

Publication Number Publication Date
HRP20220463T1 true HRP20220463T1 (hr) 2022-05-27

Family

ID=60957267

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220463TT HRP20220463T1 (hr) 2016-12-16 2017-12-15 Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa

Country Status (27)

Country Link
US (1) US11213517B2 (hr)
EP (1) EP3554490B1 (hr)
JP (2) JP6931701B2 (hr)
KR (2) KR20210065206A (hr)
CN (1) CN110072521B (hr)
AU (2) AU2017378092B2 (hr)
BR (1) BR112019011208A2 (hr)
CA (1) CA3046846A1 (hr)
CL (1) CL2019001628A1 (hr)
DK (1) DK3554490T3 (hr)
EA (1) EA201991428A1 (hr)
ES (1) ES2908641T3 (hr)
HR (1) HRP20220463T1 (hr)
HU (1) HUE058360T2 (hr)
IL (1) IL267306B (hr)
LT (1) LT3554490T (hr)
MA (1) MA49114A (hr)
MX (1) MX2019007117A (hr)
PH (1) PH12019501314A1 (hr)
PL (1) PL3554490T3 (hr)
PT (1) PT3554490T (hr)
RS (1) RS62980B1 (hr)
SA (1) SA519401971B1 (hr)
SI (1) SI3554490T1 (hr)
TW (1) TWI808952B (hr)
UA (1) UA124977C2 (hr)
WO (1) WO2018109152A1 (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
SG11201912881SA (en) 2017-07-05 2020-01-30 Idorsia Pharmaceuticals Ltd Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
KR20220066252A (ko) 2019-07-11 2022-05-24 프락시스 프리시젼 메디신즈, 인크. T형 칼슘 채널 조절제의 제형 및 이의 사용 방법
WO2021123949A1 (en) 2019-12-20 2021-06-24 Idorsia Pharmaceuticals Ltd Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
JP2023524039A (ja) * 2020-04-29 2023-06-08 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｔ型カルシウムチャネルモジュレーターを使用する方法
WO2023240205A1 (en) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Deuterated compounds

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
US2948718A (en) 1960-08-09 New n-heterocyclic compounds
US3121076A (en) 1964-02-11 Benzodiazepinones and processes
US1025872A (en) 1911-09-06 1912-05-07 Farbenfab Vorm Bayer F & Co Phenylethylbarbituric acid.
US2554816A (en) 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
US2884444A (en) 1956-01-13 1959-04-28 Carter Prod Inc 2-phenyl-1,3 propane diol dicarbamate
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
US3984398A (en) 1966-12-14 1976-10-05 Roussel-Uclaf 1,5-Benzodiazepine-2,4-diones
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
BE795893A (fr) 1972-02-28 1973-06-18 Unicler Derives de (methylene dioxy-3,4 phenyl)-1 dimethyl-4,4 pentene-1, leur preparation et leur application en therrapeutique
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB1597796A (en) 1978-05-15 1981-09-09 Ici Ltd Primidone preparation
CS234018B2 (en) 1979-06-01 1985-03-14 Wellcome Found Method of 3,5-diammino-6-1,2,4-triazine derivatives making
US4789680A (en) 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
CA2028782C (en) 1989-11-07 2003-10-14 Christian T. Goralski Process for the production of vinyl-gaba
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
JP3056788B2 (ja) 1994-06-24 2000-06-26 ユーロ−セルティーク，エス．エイ． ホスホジエステラーゼｉｖの阻害化合物および阻害方法
IT1285801B1 (it) 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
SK86699A3 (en) 1996-12-23 2000-11-07 Du Pont Pharm Co Nitrogen containing heteroaromatics as factor xa inhibitors
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
EP1359911A2 (en) 2000-12-29 2003-11-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ivc
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
ATE455104T1 (de) 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
AU2002359714B2 (en) 2001-12-18 2006-12-21 Merck Sharp & Dohme Corp. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
ES2292854T3 (es) 2001-12-18 2008-03-16 MERCK & CO., INC. Moduladores triazol sustituidos con heteroarilo del receptor-5 metabotropico de glumatamato.
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
WO2004089303A2 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1613617A4 (en) 2003-04-04 2009-02-18 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
GEP20115305B (en) 2004-08-18 2011-10-10 Pfizer Inhibitors of hepatitis c virus rna-dependent rna polymerase, compositions containing them and using the same for treatment
DE602005013116D1 (de) 2004-12-23 2009-04-16 Glaxo Group Ltd Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
GB0515690D0 (en) 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
CA2634147A1 (en) 2005-12-22 2007-06-28 Icagen, Inc. Calcium channel antagonists
RU2008144571A (ru) 2006-04-12 2010-05-20 Мерк энд Ко., Инк. (US) Пиридиламидные антагонисты кальциевых каналов т-типа
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
BRPI0715531A2 (pt) 2006-07-24 2014-06-24 Hoffmann La Roche Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US20110038850A1 (en) 2007-01-05 2011-02-17 Didier Bagnol G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders
JP5478488B2 (ja) 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Ｊａｎｕｓキナーゼの阻害剤
US20090030403A1 (en) * 2007-07-27 2009-01-29 Leyde Kent W Methods and Systems for Attenuating the Tolerance Response to a Drug
CN101827832B (zh) 2007-10-08 2014-05-07 阿德维纳斯治疗私人有限公司 作为葡糖激酶活化剂的乙酰胺衍生物、其制备方法及医药应用
JP5524071B2 (ja) 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
US20100216816A1 (en) 2007-10-24 2010-08-26 Barrow James C Pyrazinyl amide-t type calcium channel antagonists
US20100249176A1 (en) 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
WO2009118596A2 (en) 2008-03-26 2009-10-01 Glenmark Pharmaceuticals, S. A. Phthalimide derivatives as trpa1 modulators
JP2011516442A (ja) 2008-04-04 2011-05-26 ビオマリン アイジーエー リミテッド 筋ジストロフィーを治療するための化合物
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
JP2012524755A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのｎ−ピラゾリルカルボキサミド
CA2763821A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1h-imidazo[4,5-c]quinolinone derivatives
WO2011022315A1 (en) 2009-08-19 2011-02-24 Merck Sharp & Dohme Corp. Pyrazinyl phenyl amide t-type calcium channel antagonists
US8987310B2 (en) 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
CA2782885A1 (en) 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
WO2012027322A1 (en) 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
JP2014510714A (ja) 2011-01-18 2014-05-01 グラクソ グループ リミテッド レチガビンの製造方法
UA107423C2 (en) 2011-03-07 2014-12-25 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
EP2747770A1 (en) * 2011-08-26 2014-07-02 BIAL - Portela & Cª S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9868748B2 (en) 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
AR096393A1 (es) 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
CN103948553A (zh) * 2014-04-22 2014-07-30 青岛市中心医院 一种拉莫三嗪缓释片及其制备方法
KR101685993B1 (ko) 2014-05-15 2016-12-13 한국과학기술연구원 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
NZ727818A (en) 2014-06-03 2020-06-26 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
MX367519B (es) 2014-09-15 2019-08-26 Idorsia Pharmaceuticals Ltd Compuestos triazolicos como bloqueadores de canales de calcio tipo t.
CA2975474C (en) 2015-01-30 2023-06-13 Neurocrine Biosciences, Inc. Substituted triazoles and methods relating thereto
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
SG11201912881SA (en) 2017-07-05 2020-01-30 Idorsia Pharmaceuticals Ltd Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide

Also Published As

Publication number Publication date
MA49114A (fr) 2020-03-25
UA124977C2 (uk) 2021-12-22
TWI808952B (zh) 2023-07-21
SI3554490T1 (sl) 2022-04-29
PH12019501314A1 (en) 2020-03-02
JP2019536788A (ja) 2019-12-19
CA3046846A1 (en) 2018-06-21
AU2017378092B2 (en) 2023-11-23
JP2020180138A (ja) 2020-11-05
JP7198792B2 (ja) 2023-01-04
MX2019007117A (es) 2019-09-16
PL3554490T3 (pl) 2022-05-30
KR20190096381A (ko) 2019-08-19
CN110072521B (zh) 2022-11-29
EP3554490B1 (en) 2022-02-16
KR20210065206A (ko) 2021-06-03
DK3554490T3 (da) 2022-02-28
CN110072521A (zh) 2019-07-30
IL267306B (en) 2022-07-01
EA201991428A1 (ru) 2019-12-30
SA519401971B1 (ar) 2022-12-27
HUE058360T2 (hu) 2022-07-28
KR102296653B1 (ko) 2021-09-01
AU2017378092A1 (en) 2019-07-25
IL267306A (en) 2019-08-29
PT3554490T (pt) 2022-03-17
CL2019001628A1 (es) 2019-11-15
RS62980B1 (sr) 2022-03-31
US20200016139A1 (en) 2020-01-16
AU2023282336A1 (en) 2024-01-18
EP3554490A1 (en) 2019-10-23
JP6931701B2 (ja) 2021-09-08
ES2908641T3 (es) 2022-05-03
BR112019011208A2 (pt) 2019-10-15
US11213517B2 (en) 2022-01-04
WO2018109152A1 (en) 2018-06-21
LT3554490T (lt) 2022-04-25
TW201827048A (zh) 2018-08-01

Similar Documents

Publication Publication Date Title
HRP20220463T1 (hr) Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
RU2016122563A (ru) Тетрагидробензодиазепиноны
RU2425838C2 (ru) Ингибиторы iap
RU2401658C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
JP2013516395A5 (hr)
Clézardin Therapeutic targets for bone metastases in breast cancer
RU2223116C2 (ru) Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p
JP2003528859A5 (hr)
RU2002128916A (ru) Арилзамещенные пиразолы, триазолы или тетразолы (варианты), фармацевтическая композиция, способ лечения заболевания, связанного с блокированием натриевых каналов, у млекопитающего, способ лечения, профилактики или снижения интенсивности различных нарушений или состояний, способ снижения интенсивности или профилактики приступов у животного
HRP20172006T1 (hr) Derivati pirazol-aminopiridina kao lrrk2-modulatori
CA2575003A1 (en) Potassium channel inhibitors
HRP20220936T1 (hr) Heterociklički amidi korisni kao modulatori proteina
HRP20150082T1 (hr) Derivati pirazolo piridina kao inhibitori nadph oksidaze
SI3075726T1 (en) DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS
JP2020502229A5 (hr)
IL188583A0 (en) Pharmaceutical dosage form containing an active principle combination of nifedipine and/or nisoldipine and of an angiotensin ii antagonist
ES2274234T3 (es) 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3(4-piridin-3-il)pirimidin -2-ilamino)fenil)-benzamida para el tratamiento de enfermedades mediadas por ang ii.
ES2206304T3 (es) Particulas de velocidad controlada.
RU2009111378A (ru) Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5
HRP20100401T1 (hr) DERIVATI PIRAZOLO/3,4-d/AZEPINA KAO HISTAMINSKI H3 ANTAGONISTI
JP2009500366A5 (hr)
ZA200200997B (en) Use of CGRP antagonists and CGRP release inhibitors for controlling menopausal hot flushes.
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
JP2009532438A5 (hr)
ECSP22098275A (es) Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina